PLD1 and Alzheimer disease: Since the 12-month-old 3xTg-AD mice are reported to show both Aβ and tau pathologies [45,46,48,50], we rationalized that the assessment of both LTP and LTD at this age will be needed to completely understand the therapeutic potential of PLD1 chronic inhibition.